Julien Dodet

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Med LLC develops targeted cancer therapies using lead-212 (212Pb). The company is based in Bethesda, MD. The company is ultimately controlled by the Government of France. The CEO of the company is Julien Dodet.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Orano Med LLC develops targeted cancer therapies using lead-212 (212Pb). The company is based in Bethesda, MD. The company is ultimately controlled by the Government of France. The CEO of the company is Julien Dodet.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.